In vivo pharmacological profile of SL 84.0418, a new selective, peripherally active α2-adrenoceptor antagonist

European Journal of Pharmacology

Volumn 234, Issue 2-3, 1993, Pages 137-145

  Angel, Itzchak ^a   Grosset, Alain ^a   Perrault, Ghislaine ^a   Schoemaker, Hans ^a   Langer, Salomon Z ^a  

^a SANOFI   (France)

Author keywords

(Peripheral activity); SL 84.0418; 2 Adrenoceptors

Indexed keywords

1,2,4,5 TETRAHYDRO 2 (2 IMIDAZOLIN 2 YL) 2 PROPYLPYRROLO[3,2,1 HI]INDOLE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CIRAZOLINE; CLONIDINE; IDAZOXAN; NORADRENALIN; PRAZOSIN; SL 860714; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SELECTIVITY; ENANTIOMER; HEART RATE; HYPERGLYCEMIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPINAL CORD LESION; STEREOSPECIFICITY; TACHYCARDIA; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMAL; BLOOD GLUCOSE; BLOOD PRESSURE; CLONIDINE; DECEREBRATE STATE; DIOXANES; EPINEPHRINE; HEART RATE; HYPERGLYCEMIA; IDAZOXAN; INDOLES; MALE; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PERIPHERAL NERVES; PRAZOSIN; PYRROLES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; VASOCONSTRICTION;

EID: 0027410093     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(93)90947-G     Document Type: Article

References (31)

1. 2-adrenoceptirs
2. Pharmacological characterization of the hyperglycaemia induced by alpha-2 adrenoceptor agonists
3. 2-antagonist with anti-hyperglycemic properties
4. SL 84.0418: a novel, potent and selective alpha-2 adrenoceptor antagonist: I. In vitro pharmacological profile
5. α-Blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus
6. + channels in insulin-secreting cells
7. α-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on α-adrenoceptor activity
8. A peripherally acting alpha-2-adrenoceptor antagonist: L-659,066
9. Depression of exploratory activity by clonidine in rats as a model for the detection of relative pre- and postsynaptic central noradrenergic receptor selectivity of alpha adrenolytic drugs
10. Neuropharmacological studies in rodents on the action of RX 781094, a new selective alpha-2 adrenoceptor antagonist
11. 2-adrenoceptor agonists
12. 2-adrenoceptors
13. Selectivity and potency of 2-alkyl analogues of the alpha-2 adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems
14. 2-adrenoceptors by L-659,066 enhances glucose tolerance and insulin release in mice
15. Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and postjunctional alpha-2 adrenoceptors
16. 2-antagonist SL 84.0418 in the primate (Macaca fascicularis) in comparison with idazoxan
17. Presynaptic regulation of catecholamines release
18. Presynaptic receptors
19. Presynaptic regulation of the release of catecholamines
20. Pharmacologic and therapeutic significance of α-adrenoceptor subtypes
21. Alpha-2 adrenoceptor antagonism and other pharmacological antagonist properties of some substituted benzoquinolizines and yohimbine in vitro
22. Regulation of glycogenolysis by neurotransmitters in the central nervous system
23. Alpha-adrenoceptors: a critical review
24. Induction of defective insulin secretion and impaired glucose tolerance by clonidine, Selective stimulation of metabolic alpha-adrenergic pathways
25. 2-Adrenoceptor blockade does not enhance glucose-induced release in normal subjects or patients with non-insulin dependent diabetes
26. 2-adrenoceptor antagonist
27. 2-adrenoceptor antagonist, L-657,743
28. The insulin secreting cell line, RINm5F, expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan-binding sites
29. A role of alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus
30. Stress and autonomic nervous system in type II diabetes, A hypothesis
31. CH-38083, a selective, potent antagonist of alpha-2 adrenoceptors